Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy

Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells

(2022) Naomi Kawashima et al.   Nature Communications

Rapid Profiling of Tumor‐Immune Interaction Using Acoustically Assembled Patient‐Derived Cell Clusters

(2022) Zheng Ao et al.   Advanced Science

Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma

(2021) Chen Huang et al.   CANCER CELL

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

(2021) Xing Yi Woo et al.   NATURE GENETICS

Head and neck cancer

(2021) Mayur D Mody et al.   LANCET

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

(2021) Philippe Moreau et al.   LANCET ONCOLOGY

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening

(2021) Gadi Lalazar et al.   Cancer Discovery

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53

(2021) Joanna S. Yi et al.   NEOPLASIA

Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions

(2021) Leilei Fu et al.   Acta Pharmaceutica Sinica B

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

(2021) Leticia De Mattos-Arruda et al.   npj Breast Cancer

Comprehensive pharmacogenomics characterization of temozolomide response in gliomas

(2021) Shuangmei Tong et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Comprehensive pharmacogenomic characterization of gastric cancer

(2020) Jason K. Sa et al.   Genome Medicine

Microtubule engagement with taxane is altered in taxane-resistant gastric cancer

(2020) Giuseppe Galletti et al.   CLINICAL CANCER RESEARCH

Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline

(2020) Ellie Maghami et al.   JOURNAL OF CLINICAL ONCOLOGY

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

(2020) Moshe Talpaz et al.   LEUKEMIA

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

(2020) Vivek Subbiah et al.   LANCET ONCOLOGY

PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma

(2020) Tian-Yi Jiang et al.   Science Translational Medicine

Head and neck squamous cell carcinoma

(2020) Daniel E. Johnson et al.   Nature Reviews Disease Primers

PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition

(2019) Vaishnavi Sambandam et al.   CLINICAL CANCER RESEARCH

Oral mucosal organoids as a potential platform for personalized cancer therapy

(2019) Else Driehuis et al.   Cancer Discovery

KRT18 is correlated with the malignant status and acts as an oncogene in colorectal cancer

(2019) Jingfeng Zhang et al.   BIOSCIENCE REPORTS

The changing therapeutic landscape of head and neck cancer

(2019) John D. Cramer et al.   Nature Reviews Clinical Oncology

A Pharmacogenomic Landscape in Human Liver Cancers

(2019) Zhixin Qiu et al.   CANCER CELL

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

(2019) Luca Lazzari et al.   CLINICAL CANCER RESEARCH

Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype

(2019) Daehwan Kim et al.   NATURE BIOTECHNOLOGY

Statistical predictions with glmnet

(2019) Solveig Engebretsen et al.   Clinical Epigenetics

Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models

(2019) Okada et al.   Cells

ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells

(2019) Mingyang Liu et al.   GASTROENTEROLOGY

Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy

(2018) Yue Zhao et al.   GUT

Drug sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy

(2018) Tatiana Lepikhova et al.   MOLECULAR CANCER THERAPEUTICS

Chromosomal instability drives metastasis through a cytosolic DNA response

(2018) Samuel F. Bakhoum et al.   NATURE

Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

(2018) Hervé Tiriac et al.   Cancer Discovery

Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy

(2018) Jin-Ku Lee et al.   NATURE GENETICS

Systematic identification of non-coding pharmacogenomic landscape in cancer

(2018) Yue Wang et al.   Nature Communications

Optimizing Cancer Treatment Using Game Theory

(2018) Katerina Stanková et al.   JAMA Oncology

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

(2018) Y -P Chen et al.   ANNALS OF ONCOLOGY

Drug repurposing: progress, challenges and recommendations

(2018) Sudeep Pushpakom et al.   NATURE REVIEWS DRUG DISCOVERY

Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma

(2018) Christina Karamboulas et al.   Cell Reports

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Denis Soulières et al.   LANCET ONCOLOGY

Application of Combination High-Throughput Phenotypic Screening and Target Identification Methods for the Discovery of Natural Product-Based Combination Drugs

(2017) Monica Isgut et al.   MEDICINAL RESEARCH REVIEWS

Functional precision cancer medicine—moving beyond pure genomics

(2017) Anthony Letai   NATURE MEDICINE

Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device

(2017) Bee Luan Khoo et al.   Nature Protocols

Opportunities and challenges in phenotypic drug discovery: an industry perspective

(2017) John G. Moffat et al.   NATURE REVIEWS DRUG DISCOVERY

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study

(2017) Berend Snijder et al.   Lancet Haematology

Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics

(2017) Marc Hafner et al.   Scientific Data

Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas

(2016) E. Gaudio et al.   ANNALS OF ONCOLOGY

Conpair: concordance and contamination estimator for matched tumor–normal pairs

(2016) Ewa A. Bergmann et al.   BIOINFORMATICS

Stress Chaperone Mortalin Contributes to Epithelial-to-Mesenchymal Transition and Cancer Metastasis

(2016) Y. Na et al.   CANCER RESEARCH

A Landscape of Pharmacogenomic Interactions in Cancer

(2016) Francesco Iorio et al.   CELL

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

(2016) Alejandra Bruna et al.   CELL

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2016) S. O. Dolly et al.   CLINICAL CANCER RESEARCH

Reverse Pharmacognosy and Reverse Pharmacology; Two Closely Related Approaches for Drug Discovery Development

(2016) Soodabeh Saeidnia et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

(2016) Jessica L. Geiger et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Reproducible pharmacogenomic profiling of cancer cell line panels

(2016) Peter M. Haverty et al.   NATURE

Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs

(2016) Marc Hafner et al.   NATURE METHODS

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

(2015) Jean-Pascal H Machiels et al.   LANCET ONCOLOGY

Mitoxantrone, More than Just Another Topoisomerase II Poison

(2015) Benny J. Evison et al.   MEDICINAL RESEARCH REVIEWS

miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics

(2015) K. Sossey-Alaoui et al.   MOLECULAR CANCER RESEARCH

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

Predicting Cancer Drug Response: Advancing the DREAM

(2015) R. B. Altman   Cancer Discovery

Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas

(2015) P. S. Hammerman et al.   Cancer Discovery

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset

(2015) B. Seashore-Ludlow et al.   Cancer Discovery

On Chip Analysis of CNS Lymphoma in Cerebrospinal Fluid

(2015) Anna Turetsky et al.   Theranostics

GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma

(2014) C. Z. Yang et al.   ANNALS OF ONCOLOGY

TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)†

(2014) V. Grünwald et al.   ANNALS OF ONCOLOGY

Unbiased Compound Screening Identifies Unexpected Drug Sensitivities and Novel Treatment Options for Gastrointestinal Stromal Tumors

(2014) S. Boichuk et al.   CANCER RESEARCH

Insights into drug discovery from natural medicines using reverse pharmacokinetics

(2014) Haiping Hao et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules

(2013) Amrita Basu et al.   CELL

Phenotypic screens as a renewed approach for drug discovery

(2013) Wei Zheng et al.   DRUG DISCOVERY TODAY

Targeting SOD1 reduces experimental non–small-cell lung cancer

(2013) Andrea Glasauer et al.   JOURNAL OF CLINICAL INVESTIGATION

Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

(2013) L.-P. Zhong et al.   MOLECULAR CANCER THERAPEUTICS

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Metrics other than potency reveal systematic variation in responses to cancer drugs

(2013) Mohammad Fallahi-Sichani et al.   Nature Chemical Biology

Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes

(2013) Vonn Walter et al.   PLoS One

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma

(2012) Lai-ping Zhong et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

(2011) A. Argiris et al.   CLINICAL CANCER RESEARCH

Integrative genomics viewer

(2011) James T Robinson et al.   NATURE BIOTECHNOLOGY

A framework for variation discovery and genotyping using next-generation DNA sequencing data

(2011) Mark A DePristo et al.   NATURE GENETICS

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

(2011) Craig H Mermel et al.   GENOME BIOLOGY

Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

(2010) Pol Specenier et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation

(2010) Cole Trapnell et al.   NATURE BIOTECHNOLOGY

The Sequence Alignment/Map format and SAMtools

(2009) H. Li et al.   BIOINFORMATICS

Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck

(2009) Byoung Chul Cho et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth

(2009) K. Iljin et al.   CLINICAL CANCER RESEARCH